@article{e4c20a4233154ead91f9a3b805eeeae3,
title = "Quality control for retinal OCT in multiple sclerosis: Validation of the OSCAR-IB criteria",
abstract = "Background: Retinal optical coherence tomography (OCT) permits quantification of retinal layer atrophy relevant to assessment of neurodegeneration in multiple sclerosis (MS). Measurement artefacts may limit the use of OCT to MS research. Objective: An expert task force convened with the aim to provide guidance on the use of validated quality control (QC) criteria for the use of OCT in MS research and clinical trials. Methods: A prospective multi-centre (n = 13) study. Peripapillary ring scan QC rating of an OCT training set (n = 50) was followed by a test set (n = 50). Inter-rater agreement was calculated using kappa statistics. Results were discussed at a round table after the assessment had taken place. Results: The inter-rater QC agreement was substantial (kappa = 0.7). Disagreement was found highest for judging signal strength (kappa = 0.40). Future steps to resolve these issues were discussed. Conclusion: Substantial agreement for QC assessment was achieved with aid of the OSCAR-IB criteria. The task force has developed a website for free online training and QC certification. The criteria may prove useful for future research and trials in MS using OCT as a secondary outcome measure in a multicentre setting.",
keywords = "Atrophy, Multiple sclerosis, Outcome measurement, Progressive",
author = "S. Schippling and Balk, {L. J.} and F. Costello and P. Albrecht and L. Balcer and Calabresi, {P. A.} and Frederiksen, {J. L.} and E. Frohman and Green, {A. J.} and A. Klistorner and O. Outteryck and F. Paul and Plant, {G. T.} and G. Traber and P. Vermersch and P. Villoslada and S. Wolf and A. Petzold",
note = "Funding Information: Friedemann Paul is supported by the German Research Council (DFG Exc 257) and by the German Ministry of Education and Research (BMBF {\textquoteleft}Competence Network Multiple Sclerosis{\textquoteright}). Funding Information: Philipp Albrecht received research grants from Novartis, Biogen Idec, Teva, Merz Pharmaceuticals, and travel/accommodations/meeting expenses by Novartis, Teva, Biogen Idec, Merz Pharmaceuticals, Ipsen, Esai, and Glaxo Smith Kline. Funding Information: Peter Calabresi has received personal compensation for consulting and serving on scientific advisory boards from Vertex, Vaccinex, Prothena, and Abbott, has received research funding from companies; Biogen-IDEC and Novartis, and is supported by NIH, R01 NS082347. Funding Information: Sven Schippling is supported by the Betty and David Koetser Foundation for Brain Research and the Clinical Research Priority Program of the University of Zurich, Zurich, Switzerland. Publisher Copyright: {\textcopyright} The Author(s), 2015.",
year = "2015",
month = feb,
day = "17",
doi = "10.1177/1352458514538110",
language = "English (US)",
volume = "21",
pages = "163--170",
journal = "Multiple Sclerosis Journal",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "2",
}